Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas.

Nancy AlnassarJonathan M J DerryGiuseppe Luigi BannaDariusz C Górecki

Published in: Translational lung cancer research (2024)

transcript expression can guide treatment strategies in mesothelioma, informing decisions regarding treatment intensity, follow-up schedules, eligibility for clinical trials, and ultimately, end-of-life care planning.

Keyphrases

clinical trial
poor prognosis
high intensity
rna seq
long non coding rna
phase ii
single cell